



Enterome's GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-re publication NAR Genomics and Bioinformatics

Enterome developed GeneMark-HM software in collaboration with Gene Probe Inc.

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its un de-code the molecular interactions in the gut microbiome impacting human health, announces the capabilities of its proprietary GeneMark-HM software have been highlighted in NAR Genomics and Bi peer-reviewed publication. GeneMark-HM was developed to accurately mine potential drug ca Enterome's database of microbiome proteins, the largest in the world. Enterome worked in collaborat Probe Inc, a specialist in gene prediction software, to create GeneMark-HM.

GeneMark-HM is a computational pipeline (i.e. a chain of genomic information processing too developed to enhance the reliability of Enterome's drug discovery platform and accelerate the disc candidates.

The publication showed that GeneMark-HM improves the accuracy of gene prediction in huma metagenomic sequences in comparison with current state-of-art gene prediction tools. This imp clearly seen:

- in the whole gene prediction sensitivity as well as
- in the accuracy of the gene starts prediction

In an assessment of gene accuracy, outlined in the publication on benchmark metagenomic s GeneMark-HM pipeline showed the lowest rate of errors in gene recognition and the lowest percenta starts compared to current state-of-the-art gene prediction tools.

Mark Borodovsky, CEO of Gene Probe Inc., said: *"GeneMark-HM is the first of its kind gene predicti the human microbiome. It was specifically trained on genomes of thousands of species present microbiome to detect genes and gene starts in earlier seen and, most importantly, yet unseen genom with high accuracy. I am delighted that we were able to work with Enterome to develop this in computational instrument for machine learning from known data, with the aim to infer new kn powerful gene discovery tool will allow Enterome to create new and potentially transformative drugs. will also be very useful for the global academic community of molecular biologists and bioinformatici comparative, functional and evolutionary microbial genomics."*

Francesco Strozzi, Head of the Data Science department at Enterome, said: *"It was a pleasure to wo highly knowledgeable team at Gene Probe. GeneMark-HM has allowed Enterome to improve its abili human microbiome and identify potential drug candidates with high reliability, paving the way for discovery process compared to industry' norms. We intend to use this pipeline to generate potential drugs to significantly improve global healthcare."*

Publication reference: GeneMark-HM: improving gene prediction in DNA sequences of human m Lomsadze and all, NAR Genomics and Bioinformatics, 2021 (1-11), doi:10.1093/nargab/lqab047 – [Link](#)

Contacts

Enterome

Marine Perrier

Head of External Communications and Investor Relations

investorrelations@enterome.com

Media Relations

Mark Swallow / Sylvie Berrebi / David Dible

Citigate Dewe Rogerson

Tel. +44 207 638 9571

enterome@citigatedewerogerson.com

About Enterome

Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique a code molecular interactions in the gut microbiome impacting human health. Enterome's success is ba unique ability to identify small proteins and peptides ("effectors") from gut bacteria that can deliver a t benefit in humans.

Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre candidates with a focus on cancer, inflammatory and metabolic diseases:

OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). E Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is about to enter development for indolent non-Hodgkin B-cell lymphomas.

EndoMimics: a new generation of biologics targeting inflammatory diseases (EM101) and metabol such as Type 2 diabetes.

These pipelines have been created using Enterome's highly efficient proprietary drug discovery platform machine learning and lab assays to interrogate and decode the world's largest database of gut bacteria unique source of novel precision drugs.

In addition, Enterome's clinical candidate Sibofimloc (also referred to as TAK-018) is advancing through clinical trials in Crohn's disease. Sibofimloc has been partnered with Takeda globally, with Enterome re significant profit share in the US.

Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.

94/96 avenue Ledru-Rollin
75011 PARIS, FRANCE
Tel : +33 (0)1 75 77 27 85

RCS Paris N° 508 580 289
Siret : 50858028900025
NAF : 7211Z
N° TVA : FR40 508 580 289